Regarding the individual CLL treatments detected during the study period, the BTK inhibitor ibrutinib was the most commonly used in both lines of treatment studied, reflecting its rapid positioning in clinical practice after receiving marketing authorization by the European Medicines Agency in 2014 and by the Spanish Agency of Medicines and Medical Devices in 2016 [48]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.